



5.21.089

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Antineoplastic Agents	Original Policy Date:	April 7, 2017
Subject:	Bavencio	Page:	1 of 5

Last Review Date: March 6, 2026

Bavencio

Description

Bavencio (avelumab)

Background

Bavencio (avelumab) is a programmed death ligand-1 (PD-L1) blocking antibody. This interaction releases the inhibitory effects of PD-L1 on the immune response resulting in the restoration of immune responses, including anti-tumor immune responses. Bavencio has also been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro (1).

Regulatory Status

FDA-approved indications: Bavencio is a programmed death ligand-1 (PD-L1) blocking antibody indicated for:

1. Merkel Cell Carcinoma (MCC)
 - a. Adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC)
2. Urothelial Carcinoma (UC)
 - a. Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy
 - b. Patients with locally advanced or metastatic urothelial carcinoma who:
 - i. Have disease progression during or following platinum-containing chemotherapy
 - ii. Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
3. Renal Cell Carcinoma (RCC)

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Antineoplastic Agents	Original Policy Date:	April 7, 2017
Subject:	Bavencio	Page:	2 of 5

- a. First-line treatment, in combination with axitinib, of patients with advanced renal cell carcinoma (RCC)

Bavencio can cause immune-mediated pneumonitis, hepatitis, colitis, and nephritis. Monitor patients for signs and symptoms of these adverse reactions and evaluate patients suspected of them. Discontinue Bavencio if the immune-mediated reactions become life-threatening (1).

Bavencio can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should use effective contraception while taking Bavencio and for one month after completion or discontinuation of therapy (1).

Bavencio in combination with axitinib can cause hepatotoxicity with higher than expected frequencies of Grade 3 and 4 ALT and AST elevation. More frequent monitoring of liver enzymes should be considered. Bavencio with axitinib can also cause severe and fatal cardiovascular events. Baseline and periodic evaluations of left ventricular ejection fraction (LVEF) should be considered, as well as monitoring for signs and symptoms of cardiovascular events (1).

The safety and effectiveness of Bavencio have not been established in pediatric patients less than 12 years of age (1).

Related policies

Keytruda, Opdivo

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Bavencio may be considered **medically necessary** if the conditions indicated below are met.

Bavencio may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 12 years of age or older

Diagnoses

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Antineoplastic Agents	Original Policy Date:	April 7, 2017
Subject:	Bavencio	Page:	3 of 5

Patient must have **ONE** of the following:

1. Metastatic Merkel cell carcinoma (MCC)
2. Locally advanced or metastatic urothelial carcinoma with **ONE** of the following:
 - a. **NO** disease progression with first-line platinum-containing chemotherapy
 - a. Used as maintenance treatment
 - b. Disease progression during or following platinum-containing chemotherapy
 - c. Disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
3. Advanced renal cell carcinoma (RCC)
 - a. Used in combination with Inlyta (axitinib)
 - b. First-line treatment
 - c. Liver enzymes will be monitored
 - d. Patient will be monitored for cardiovascular events

AND ALL of the following:

- a. Prescriber agrees to monitor for all immune-mediated adverse reactions and discontinue therapy if necessary
- b. Female patients of reproductive potential **only**: patient will be advised to use effective contraception during therapy and for at least 1 month after the last dose

Prior – Approval *Renewal* Requirements

Age 12 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Metastatic Merkel cell carcinoma (MCC)
2. Locally advanced or metastatic urothelial carcinoma
3. Advanced renal cell carcinoma (RCC)

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Antineoplastic Agents	Original Policy Date:	April 7, 2017
Subject:	Bavencio	Page:	4 of 5

- a. Used in combination with Inlyta (axitinib)
- b. Liver enzymes will be monitored
- c. Patient will be monitored for cardiovascular events

AND ALL of the following:

- a. **NO** disease progression or unacceptable toxicity
- b. Prescriber agrees to monitor for all immune-mediated adverse reactions and discontinue therapy if necessary
- c. Female patients of reproductive potential **only**: patient will be advised to use effective contraception during therapy and for at least 1 month after the last dose

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Duration 12 months

Prior – Approval *Renewal* Limits

Same as above

Rationale

Summary

Bavencio (avelumab) is a programmed death ligand-1 (PD-L1) blocking antibody. This interaction releases the inhibitory effects of PD-L1 on the immune response resulting in the restoration of immune responses, including anti-tumor immune responses. Bavencio has also been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. The safety and effectiveness of Bavencio have not been established in pediatric patients less than 12 years of age (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Bavencio while maintaining optimal therapeutic outcomes.

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Antineoplastic Agents	Original Policy Date:	April 7, 2017
Subject:	Bavencio	Page:	5 of 5

References

1. Bavencio [package insert]. Rockland, MA: EMD Serono, Inc.; June 2025.
2. NCCN Drugs & Biologics Compendium[®] Avelumab 2026. National Comprehensive Cancer Network, Inc. Accessed on January 14, 2026.

Policy History

Date	Action
April 2017	Addition to PA
June 2017	Annual editorial review and reference update Addition of new indication: Locally advanced or metastatic urothelial carcinoma
June 2018	Annual editorial review and reference update
November 2018	Annual review and reference update
May 2019	Addition of indication: advanced renal cell carcinoma (RCC)
June 2019	Annual review
June 2020	Annual review
July 2020	Addition of indication: maintenance treatment of locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy. Also revised contraception requirement
September 2020	Annual review
March 2021	Annual editorial review and reference update
September 2021	Annual review and reference update
March 2022	Annual review and reference update
September 2022	Annual review and reference update
March 2023	Annual review and reference update
September 2023	Annual review and reference update
March 2024	Annual review and reference update
September 2024	Annual review and reference update
December 2024	Annual review and reference update
March 2025	Annual review and reference update
June 2025	Annual review and reference update
March 2026	Annual editorial review and reference update

Keywords

This policy was approved by the FEP[®] Pharmacy and Medical Policy Committee on March 6, 2026 and is effective on April 1, 2026.